Publications by authors named "Gregory Roloff"

Claim this Profile
C
Chimera's curse: myeloid clonal evolution after CD19-directed chimeric antigen receptor T-cell therapy.
Gregory W Roloff

Haematologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Katharine Miller

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Yannis K Valtis, Chenyu Lin, David Nemirovsky, Sean M Devlin, Kai Rejeski, Gregory W Roloff

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Miles Thomas, Hannah Johnston, Emily Dworkin, Austin Wesevich, Gregory W Roloff

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.
Ibrahim N Muhsen, Gregory W Roloff, Rawan Faramand, Tamer Othman, Yannis Valtis

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.
Hannah Lust, Liora M Schultz, Soyang Kwon, Gregory W Roloff, Ibrahim Aldoss

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
Rafael Madero-Marroquin, Joseph Cannova, Emily Dworkin, Austin Wesevich, Gregory W Roloff

EJHaem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms.
Emily O Symes, Peng Wang, Payal Sojitra, Madhu P Menon, Anand A Patel, Gregory W Roloff

Br J Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel

Haematologica· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes.
Adam Hamidi, Gregory W Roloff, Reid Shaw, Maria Acevedo, Shaili Smith

Leuk Lymphoma· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and molecular response of acute myeloid leukemia harboring non-canonical N676K driver mutations to contemporary FLT3 inhibitors.
Gregory W Roloff, Frank Wen, Aubrianna Ramsland, Andrew S Artz, Satyajit Kosuri

Haematologica· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies.
Gregory W Roloff, Reid Shaw, Timothy E O'Connor, Feighanne Hathaway, Michael W Drazer

J Genet Couns· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation.
Reid Shaw, Ali R Haque, Tyler Luu, Timothy E O'Connor, Adam Hamidi, Gregory W Roloff

Front Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy.
Timothy E O'Connor, Reid Shaw, Rafael Madero-Marroquin, Gregory W Roloff

Front Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
Caner Saygin, Gregory Roloff, Christopher N Hahn, Rakchha Chhetri, Saar Gill

Blood Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022.
Gregory W Roloff, Olatoyosi Odenike, Ashish Bajel, Andrew H Wei, Nicole Foley

Am Soc Clin Oncol Educ Book· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology.
Gregory W Roloff, Michael W Drazer, Lucy A Godley

JCO Precis Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia.
Ahmed Aleem, Ali R Haque, Gregory W Roloff, Elizabeth A Griffiths

Curr Hematol Malig Rep· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia.
Khashayar Ahmadmehrabi, Ali R Haque, Ahmed Aleem, Elizabeth A Griffiths, Gregory W Roloff

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies.
Gregory W Roloff, Lucy A Godley, Michael W Drazer

Genet Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-Generation Sequencing Delineates Clonal Origins and Informs Therapeutic Strategies in Acute Lymphoblastic Leukemia and Histiocytic Sarcoma.
Gregory W Roloff, Jeffrey I Baron, Vishala T Neppalli, Sheila Sait, Elizabeth A Griffiths

JCO Precis Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.
Hong Yuen Wong, Anthony D Sung, Katherine E Lindblad, Sheenu Sheela, Gregory W Roloff

Front Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.
Gregory W Roloff, Elizabeth A Griffiths

Hematology Am Soc Hematol Educ Program· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis